中医药治疗肝病疗效评价体系构建与思考

牛倩倩; 陈薇; 李秀惠

doi:10.12449/JCH260501

中医药治疗肝病疗效评价体系构建与思考

DOI: 10.12449/JCH260501

牛倩倩¹,
陈薇²,
李秀惠^3, , ,

1.
首都医科大学附属北京中医医院肝病科，北京 100010
2.
北京中医药大学循证医学中心，北京 100029
3.
首都医科大学附属北京佑安医院中西医结合中心，北京 100069

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：牛倩倩负责论文撰写、整理及修订；陈薇负责审阅和方法学审核；李秀惠负责研究思路设计和学术指导。

详细信息

通信作者:
李秀惠， lixiuhui@sohu.com （ORCID： 0000-0002-6707-2693）

计量
- 文章访问数: 21
- HTML全文浏览量: 6
- PDF下载量: 6
- 被引次数: 0
出版历程
- 收稿日期: 2026-03-24
- 录用日期: 2026-04-21
- 出版日期: 2026-05-20

Construction and consideration on a traditional Chinese medicine efficacy evaluation system for liver diseases

Qianqian NIU¹,
Wei CHEN²,
Xiuhui LI^{3
, ,
,}

1.
Department of Hepatology，Beijing Hospital of Traditional Chinese Medicine，Capital Medical University，Beijing 100010，China
2.
Center for Evidence-Based Chinese Medicine，Beijing University of Chinese Medicine，Beijing 100029，China
3.
Center for Integrated Traditional Chinese and Western Medicine，Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China

More Information

Corresponding author: LI Xiuhui， lixiuhui@sohu.com （ORCID： 0000-0002-6707-2693）

摘要

摘要: 中医药治疗肝病具有独特优势，但传统疗效评价主观性强、标准化不足，现代医学评价标准又难以契合中医药干预特色，“病-症-证分离”现象突出。针对上述问题，本文提出以“病-症-证结合”为核心理念，构建融合中医证候疗效、患者报告结局、疾病总体转归、生物学指标演变的四维疗效评价体系。文章系统阐释了各维度核心内涵、指标遴选原则及量化方法，明确体系实施原则与具体实施策略，旨在为推动中医肝病领域开展高质量临床研究、产出高级别循证证据提供方法学支撑，助力中医药诊疗的现代化及国际化传播。
- 肝疾病 /
- 中医药疗法 /
- 治疗结果
Abstract: Traditional Chinese medicine （TCM） has unique advantages in the management of liver diseases； however， traditional TCM efficacy evaluation is highly subjective with a lack of standardized criteria， and the evaluation criteria for modern medicine are incompatible with the characteristics of TCM interventions， leading to a marked dissociation between diseases， symptoms， and syndromes. To address the above issues， this article proposes the core principle of disease-symptom-syndrome integration and establishes a four-dimensional efficacy evaluation system including TCM syndrome efficacy， patient-reported outcomes， overall disease prognosis， and changes in biological indicators. This article systematically elaborates on the core connotation， indicator selection criteria， and quantification methods of each dimension and clarifies the implementation principles and strategies， in order to provide methodological support for high-quality clinical research and the production of high-level evidence-based data in TCM treatment of liver diseases and promote the modernization and internationalization of TCM diagnosis and treatment.
- Liver Diseases /
- Traditional Chinese Medicine Therapy /
- Treatment Outcome

HTML全文

注： LSM，肝硬度值；CLDQ，慢性肝病问卷；SF-36，健康调查简表；PSQI，匹兹堡睡眠量表；VAS，视觉模拟评分；NRS，数字评定量表。

图 1 中医治疗肝纤维化四维疗效评价

Figure 1. Four-Dimensional efficacy evaluation of traditional Chinese medicine in the treatment of hepatic fibrosis

下载: 全尺寸图片幻灯片

参考文献(23)

[1]	ZHANG JH, SUN XH, GAO YQ. Review and commentary on progress of traditional Chinese medicine for liver cirrhosis reversal and recompensation[J]. Chin J Integr Tradit West Med Liver Dis, 2025, 35( 3): 265- 268. DOI: 10.3969/j.issn.1005-0264.2025.003.001. 张景豪, 孙学华, 高月求. 肝硬化逆转及再代偿中医药防治进展述评[J]. 中西医结合肝病杂志, 2025, 35( 3): 265- 268. DOI: 10.3969/j.issn.1005-0264.2025.003.001.
[2]	LU FM, FENG B, ZHENG SJ, et al. Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t) ide analogues[J]. J Clin Hepatol, 2021, 37( 6): 1268- 1274. DOI: 10.3969/j.issn.1001-5256.2021.06.007. 鲁凤民, 封波, 郑素军, 等. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021, 37( 6): 1268- 1274. DOI: 10.3969/j.issn.1001-5256.2021.06.007.
[3]	LAN XX, CHEN H, SUN YN, et al. Review on the current status and strategies of TCM syndrome efficacy evaluation[J]. Chin J Inf Tradit Chin Med, 2025, 32( 12): 183- 186. DOI: 10.19879/j.cnki.1005-5304.202502460. 兰晓雪, 陈红, 孙亚男, 等. 中医证候疗效评价研究现况及策略述评[J]. 中国中医药信息杂志, 2025, 32( 12): 183- 186. DOI: 10.19879/j.cnki.1005-5304.202502460.
[4]	ZHANG P, XU BC, WANG Y, et al. Research status and problem analysis of therapeutic effect iveness evaluation indicators in traditional Chinese medicine[J]. China J Tradit Chin Med Pharm, 2025, 40( 6): 3152- 3158. 张彭, 徐百川, 王艳, 等. 中医药疗效评价指标的研究现状梳理与问题分析[J]. 中华中医药杂志, 2025, 40( 6): 3152- 3158.
[5]	XUE FF, HAO WZ, CHEN JX. Application of analytic hierarchy process in standardization of traditional Chinese medicine syndrome[J]. China J Tradit Chin Med Pharm, 2025, 40( 1): 271- 274. 薛飞飞, 郝闻致, 陈家旭. 层次分析法在中医证候标准化研究的应用探讨[J]. 中华中医药杂志, 2025, 40( 1): 271- 274.
[6]	ZHANG YH, LIU BY, LIU ZS, et al. PRO and clinical efficacy evaluation of traditional Chinese medicine[J]. J Tradit Chin Med, 2007, 48( 8): 680- 682. DOI: 10.3321/j.issn: 1001-1668.2007.08.002. 张艳宏, 刘保延, 刘志顺, 等. PRO与中医临床疗效评价[J]. 中医杂志, 2007, 48( 8): 680- 682. DOI: 10.3321/j.issn: 1001-1668.2007.08.002.
[7]	YOUNOSSI ZM, STEPANOVA M, YOUNOSSI I, et al. Validation of the chronic liver disease questionnaire for MASH(CLDQ-MASH)[J]. JHEP Rep, 2025, 7( 3): 101276. DOI: 10.1016/j.jhepr.2024.101276.
[8]	YOUNOSSI ZM, STEPANOVA M, YOUNOSSI I, et al. Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC[J]. Hepatol Commun, 2023, 7( 2): e0049. DOI: 10.1097/hc9.0000000000000049.
[9]	HU XJ, YAO XK, LI XK, et al. Development and evaluation of a general patient-reported outcome measure for patients with cancer[J]. Chin J Health Stat, 2025, 42( 5): 672- 678. DOI: 10.11783/j.issn.1002-3674.2025.05.006. 胡晓娟, 姚秀坤, 栗晓坤, 等. 普适性癌症患者报告结局量表的研制与评价[J]. 中国卫生统计, 2025, 42( 5): 672- 678. DOI: 10.11783/j.issn.1002-3674.2025.05.006.
[10]	FENG XC, LIN YS, ZHUO SY, et al. Treatment of obesity and metabolic-associated fatty liver disease with a diet or orlistat: A randomized controlled trial[J]. Am J Clin Nutr, 2023, 117( 4): 691- 700. DOI: 10.1016/j.ajcnut.2023.02.008.
[11]	Branch of Hepatobiliary Diseases, China Association of Chinese Medicine. Diagnosis and treatment guideline for Chinese Medicine on non-alcoholic steatohepatitis[J]. J Clin Hepatol, 2023, 39( 5): 1041- 1048. DOI: 10.3969/j.issn.1001-5256.2023.05.007. 中华中医药学会肝胆病分会. 非酒精性脂肪性肝炎中医诊疗指南[J]. 临床肝胆病杂志, 2023, 39( 5): 1041- 1048. DOI: 10.3969/j.issn.1001-5256.2023.05.007.
[12]	Chinese Association of Integrative Medicine, China Association of Chinese Medicine, Chinese Medical Association. Guidelines for integrated traditional Chinese and Western medicine diagnosis and treatment of liver cirrhosis[J]. J Clin Hepatol, 2023, 39( 11): 2543- 2549. DOI: 10.3969/j.issn.1001-5256.2023.11.005. 中国中西医结合学会, 中华中医药学会, 中华医学会. 肝硬化中西医结合诊疗指南[J]. 临床肝胆病杂志, 2023, 39( 11): 2543- 2549. DOI: 10.3969/j.issn.1001-5256.2023.11.005.
[13]	NASCIMBENI F, BEDOSSA P, FEDCHUK L, et al. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2020, 72( 5): 828- 838. DOI: 10.1016/j.jhep.2019.12.008.
[14]	WEI N, ZHENG B, CAI HF, et al. Systematic review and meta-analysis: De novo combination of nucleos(t)ide analogs and pegylated interferon alpha versus pegylated interferon alpha monotherapy for the functional cure of chronic hepatitis B[J]. Front Pharmacol, 2024, 15: 1403805. DOI: 10.3389/fphar.2024.1403805.
[15]	MAO XH, CHEUNG KS, PENG CZ, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis[J]. Hepatology, 2022, 77( 5): 1735- 1745. DOI: 10.1002/hep.32792.
[16]	SHI ZF, SONG TB, WAN Y, et al. A systematic review and meta-analysis of traditional insect Chinese medicines combined chemotherapy for non-surgical hepatocellular carcinoma therapy[J]. Sci Rep, 2017, 7: 4355. DOI: 10.1038/s41598-017-04351-y.
[17]	ROCKEY DC. Liver fibrosis reversion after suppression of hepatitis B virus[J]. Clin Liver Dis, 2016, 20( 4): 667- 679. DOI: 10.1016/j.cld.2016.06.003.
[18]	LIU Y, LIANG TX, XING FL, et al. A three-dimensional digital model for early diagnosis of hepatic fibrosis based on magnetic resonance elastography[J]. J Vis Exp, 2023( 197): e65507. DOI: 10.3791/65507.
[19]	AN ZT, WEI LF, HUANG YP, et al. Research progress on standardization and objectification of TCM syndromes of liver fibrosis[J]. Chin J Basic Med Tradit Chin Med, 2020, 26( 2): 280- 282. DOI: 10.3969/j.issn.1006-3250.2020.02.042. 安振涛, 魏兰福, 黄钰萍, 等. 肝纤维化中医证候规范化与客观化研究进展[J]. 中国中医基础医学杂志, 2020, 26( 2): 280- 282. DOI: 10.3969/j.issn.1006-3250.2020.02.042.
[20]	CHEN QJ, CHEN H, ZHANG Y, et al. Developing traditional Chinese medicine outcome indicator system for effectiveness evaluation through mixed method research[J]. J Tradit Chin Med, 2021, 62( 6): 488- 493. 陈千吉, 陈红, 张英, 等. 运用混合方法研究构建中医疗效评价指标体系初探[J]. 中医杂志, 2021, 62( 6): 488- 493.
[21]	NIU BH, ZHANG MY, CAI HZ, et al. Key points for implementation of consensus methods in the study of core outcome set in traditional Chinese medicine[J]. Mod Tradit Chin Med Mater Med World Sci Technol, 2021, 23( 8): 2576- 2579. DOI: 10.11842/wst.20210525011. 牛柏寒, 张明妍, 蔡慧姿, 等. 中医药核心指标集研究中共识方法实施要点[J]. 世界科学技术-中医药现代化, 2021, 23( 8): 2576- 2579. DOI: 10.11842/wst.20210525011.
[22]	ZHANG JH, PANG B, LI YY, et al. Overall strategy for development and application of core outcome set of traditional Chinese medicine[J]. China J Chin Mater Med, 2025, 50( 13): 3506- 3512. DOI: 10.19540/j.cnki.cjcmm.20250604.502. 张俊华, 庞博, 李毓赟, 等. 中医药核心指标集研制与应用总体策略[J]. 中国中药杂志, 2025, 50( 13): 3506- 3512. DOI: 10.19540/j.cnki.cjcmm.20250604.502.
[23]	SUN YN, HE LY, LUO L, et al. Core outcome sets of traditional Chinese medicine on the treatments of chronic hepatitis B clinical trails[J]. China J Tradit Chin Med Pharm, 2020, 35( 9): 4684- 4688. 孙亚男, 何丽云, 雒琳, 等. 中医药治疗慢性乙型肝炎临床试验的核心结局指标集研究[J]. 中华中医药杂志, 2020, 35( 9): 4684- 4688.